FDA advisory panel recommends restoring compounding rights for six key peptides

An FDA advisory committee has voted to recommend restoring compounding rights for six popular peptides, a move that would reopen legal pharmacy access to highly requested regenerative therapies for medical aesthetics clinics. On July 23, 2026, the Pharmacy Compounding Advisory Committee voted to recommend adding six out of seven reviewed peptides to the 503A Bulks List. Along with BPC-157 and TB-500, the panel recommended Epitalon, KPV, MOTS-c, and Semax, while rejecting only Emideltide.

The votes were tight, passing on narrow margins such as 8-6 and 7-5. This decision marks a significant shift from 2023, when the FDA heavily restricted access to these substances. The push to expand peptide access is currently backed by Health Secretary Robert F. Kennedy Jr. However, FDA career scientists remain strongly opposed, citing a lack of clinical trial data to prove safety and efficacy. Former FDA official Ilisa Bernstein cautioned that patient demand should not replace safety data, while committee member Haleem Mohammed emphasized the physician's primary duty to keep patients safe.

For your practice, remember that these committee votes are non-binding recommendations. The FDA retains the final authority on whether to officially allow compounding. Until the agency formally updates the 503A Bulks List, these peptides remain restricted, so you should hold off on modifying your patient offerings or ordering from compounding pharmacies until the final FDA decision is published.

Source: The Washington Post, https://www.washingtonpost.com/wellness/2026/07/24/peptides-fda-advisory-panel-rfk-jr/